Catalent’s Boerman becomes president of cell and gene therapy; plus Stanford, Intellia, Cortexyme, CZ Biohub, Grail and more

Catalent Inc. (NYSE:CTLT) said Manja Boerman will become president of cell and gene therapy, succeeding Pete Buzy, who will continue as chairman of the gene therapy business. Boerman was president of the biotech’s European biologics unit. The company closed a deal with Johnson & Johnson (NYSE:JNJ) on Wednesday to manufacture the pharma’s COVID-19 vaccine (see “J&J’s Second Manufacturing Partner”).


Read the full 598 word article

How to gain access

Continue reading with a
two-week free trial.